Yaohai Bio-Pharma, a leading CRDMO focused on microbial expression systems, has announced the launch of its new microbial biologics platform. This platform brings together more than 15 years of CRDMO experience and expanded GMP manufacturing capacity. As a result, the company is well-positioned to support global biopharmaceutical partners and accelerate global biologics development.
1. Advanced Microbial Expression Expertise
For more than 15 years, Yaohai Bio-Pharma has built strong skills in microbial strain development, microbial cell banking, and upstream and downstream process development. In addition, the team has completed over 200 projects across multiple expression systems. Through these projects, the company has created efficient processes for recombinant proteins, peptides, nucleic acids, nanobodies, and other complex molecules. Therefore, clients can expect stable performance and predictable results throughout development.
2. End-to-End Development Services
Yaohai Bio-Pharma provides full development services from gene synthesis to regulatory submission support. Because these services are fully integrated, clients often experience shorter development timelines. This advantage is especially important for projects moving through IND and NDA pathways with agencies such as the FDA, EMA, and NMPA. Moreover, the team offers practical regulatory guidance to help reduce risk at each step. We have completed over 200 projects, including 10 supporting international regulatory submissions: 7 for FDA, 1 for EMA, 2 for TGA (Australia), and 1 for Health Canada.
3. Scalable cGMP Manufacturing
The company operates five fermentation lines with a total capacity of 7,500L. These facilities are supported by modern quality control laboratories equipped with HPLC, CE, GC, and UV systems. Thanks to this setup, Yaohai Bio-Pharma maintains strong batch consistency with less than 5% variation. In addition, on-time delivery performance exceeds 99%, giving clients reliable supply as they move toward clinical or commercial stages. We support project from early R&D to commercial manufacturing, combining technical strength with regulatory knowledge to help accelerate drug development.”
Yaohai Bio-Pharma also provides flexible partnership models. As a result, both early-stage startups and large pharmaceutical companies can choose options that match their project needs.
About Yaohai Bio-Pharma
Yaohai Bio-Pharma is a CRDMO with extensive expertise in microbial expression systems. We focus on recombinant proteins, nucleic acid drugs, nanobodies, plasmid DNA, and innovative vaccines. From R&D to commercial manufacturing, we offer full-lifecycle solutions. Our mission is to build an open, integrated CRO/CDMO/MAH platform that supports global partners from discovery to market.
